Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GL-ONC1

Known as: GLV-1h68 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Light-Emitting Oncolytic Vaccinia Virus GL-ONC1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
BackgroundDespite availability of efficient treatment regimens for early stage colorectal cancer, treatment regimens for late… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
IntroductionOncolytic viruses show promise for treating cancer. However, to assess therapeutic efficacy and potential toxicity, a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA
Breast cancer is the most common cause of cancer-related death worldwide, thus remaining a crucial health problem among women… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Highly Cited
2009
Highly Cited
2009
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68
Oncolytic virotherapy of tumors has shown promising results in both preclinical and clinical studies. Here, we investigated the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2009
Highly Cited
2009
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy
We previously reported that the replication-competent vaccinia virus (VACV) GLV-1h68 shows remarkable oncolytic activity and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
A Novel Recombinant Vaccinia Virus Expressing the Human Norepinephrine Transporter Retains Oncolytic Potential and Facilitates Deep-Tissue Imaging
Noninvasive and repetitive monitoring of a virus in target tissues and/or specific organs of the body is highly desirable for the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
As a new anticancer treatment option, vaccinia virus (VACV) has shown remarkable antitumor activities (oncolysis) in preclinical… Expand
2009
2009
Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent
Mammary cancers together with cancers of the skin account for about 60% of the total cancers occurring in dogs. The veterinary… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM) is a fatal disease with a median survival of less than 14 months. For the first time, a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2007
Highly Cited
2007
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
Previously, we reported that a recombinant vaccinia virus (VACV) carrying a light-emitting fusion gene enters, replicates in, and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE